Los Angeles Capital Management LLC Purchases Shares of 13,331 Vir Biotechnology, Inc. (NASDAQ:VIR)

Los Angeles Capital Management LLC acquired a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 13,331 shares of the company’s stock, valued at approximately $119,000.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Vir Biotechnology by 9.8% in the 4th quarter. Vanguard Group Inc. now owns 12,297,139 shares of the company’s stock valued at $123,709,000 after purchasing an additional 1,096,473 shares during the last quarter. ProShare Advisors LLC raised its holdings in shares of Vir Biotechnology by 8.4% in the 1st quarter. ProShare Advisors LLC now owns 26,392 shares of the company’s stock valued at $267,000 after purchasing an additional 2,035 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Vir Biotechnology by 4.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,073 shares of the company’s stock worth $7,576,000 after buying an additional 31,405 shares during the period. Quest Partners LLC purchased a new stake in shares of Vir Biotechnology during the 4th quarter worth $258,000. Finally, Empowered Funds LLC boosted its holdings in shares of Vir Biotechnology by 8.2% in the 1st quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock valued at $4,640,000 after buying an additional 34,640 shares in the last quarter. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insiders Place Their Bets

In other news, Director Janet Napolitano sold 12,190 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the completion of the sale, the director now directly owns 11,616 shares in the company, valued at $90,604.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.60% of the stock is currently owned by company insiders.

Vir Biotechnology Price Performance

VIR opened at $7.87 on Tuesday. The firm has a fifty day moving average price of $8.89 and a 200 day moving average price of $9.46. Vir Biotechnology, Inc. has a 1 year low of $7.41 and a 1 year high of $13.09. The stock has a market cap of $1.07 billion, a P/E ratio of -1.96 and a beta of 0.46.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.13). Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. The firm had revenue of $3.08 million during the quarter, compared to analyst estimates of $7.53 million. During the same quarter last year, the company posted ($1.45) EPS. The company’s revenue was down 19.0% on a year-over-year basis. Equities analysts expect that Vir Biotechnology, Inc. will post -3.26 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC boosted their price target on Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th. HC Wainwright reiterated a “buy” rating and issued a $110.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Morgan Stanley boosted their target price on shares of Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Thursday, June 6th. Finally, Barclays increased their price target on Vir Biotechnology from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $36.80.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.